Abstract
Metabolic syndrome is defined as the clustering of multiple metabolic abnormalities, including abdominal obesity, dyslipidemia (high serum triglycerides and low serum HDL-cholesterol levels), glucose intolerance and hypertension. The pathophysiology underlying metabolic syndrome involves a complex interaction of crucial factors, but two of these, insulin resistance and obesity (especially visceral obesity), play a major role. The nuclear receptors Peroxisome Proliferator-Activated Receptors (PPAR)α and PPARγ are therapeutic targets for hypertriglyceridemia and insulin resistance, respectively. Evidence is now emerging that the PPARβ/δ isotype is a potential pharmacological target for the treatment of disorders associated with metabolic syndrome. PPARβ/δ activation increases lipid catabolism in skeletal muscle, heart and adipose tissue and improves the serum lipid profile and insulin sensitivity in several animal models. In addition, PPARβ/δ ligands prevent weight gain and suppress macrophage-derived inflammation. These data are promising and indicate that PPARβ/δ ligands may become a therapeutic option for the treatment of metabolic syndrome. However, clinical trials in humans assessing the efficacy and safety of these drugs should confirm these promising perspectives in the treatment of the metabolic syndrome.
Keywords: PPAR, fatty acid, obesity, type 2 diabetes mellitus, metabolic syndrome
Current Molecular Pharmacology
Title: Peroxisome Proliferator-Activated Receptor (PPAR)β /δ: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome
Volume: 2
Author(s): Teresa Coll, Ricardo Rodriguez-Calvo, Emma Barroso, Lucia Serrano, Elena Eyre, Xavier Palomer and Manuel Vazquez-Carrera
Affiliation:
Keywords: PPAR, fatty acid, obesity, type 2 diabetes mellitus, metabolic syndrome
Abstract: Metabolic syndrome is defined as the clustering of multiple metabolic abnormalities, including abdominal obesity, dyslipidemia (high serum triglycerides and low serum HDL-cholesterol levels), glucose intolerance and hypertension. The pathophysiology underlying metabolic syndrome involves a complex interaction of crucial factors, but two of these, insulin resistance and obesity (especially visceral obesity), play a major role. The nuclear receptors Peroxisome Proliferator-Activated Receptors (PPAR)α and PPARγ are therapeutic targets for hypertriglyceridemia and insulin resistance, respectively. Evidence is now emerging that the PPARβ/δ isotype is a potential pharmacological target for the treatment of disorders associated with metabolic syndrome. PPARβ/δ activation increases lipid catabolism in skeletal muscle, heart and adipose tissue and improves the serum lipid profile and insulin sensitivity in several animal models. In addition, PPARβ/δ ligands prevent weight gain and suppress macrophage-derived inflammation. These data are promising and indicate that PPARβ/δ ligands may become a therapeutic option for the treatment of metabolic syndrome. However, clinical trials in humans assessing the efficacy and safety of these drugs should confirm these promising perspectives in the treatment of the metabolic syndrome.
Export Options
About this article
Cite this article as:
Coll Teresa, Rodriguez-Calvo Ricardo, Barroso Emma, Serrano Lucia, Eyre Elena, Palomer Xavier and Vazquez-Carrera Manuel, Peroxisome Proliferator-Activated Receptor (PPAR)β /δ: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome, Current Molecular Pharmacology 2009; 2 (1) . https://dx.doi.org/10.2174/1874467210902010046
DOI https://dx.doi.org/10.2174/1874467210902010046 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Predictive Factors of Febrile Neutropenia Induced by Anticancer Chemotherapy in the South of Tunisia
Reviews on Recent Clinical Trials Revisiting the J-curve Phenomenon. An Old New Concept?
Current Hypertension Reviews Phytochemical, Anti-diabetic and Cardiovascular Properties of Urtica dioica L. (Urticaceae): A Review
Mini-Reviews in Medicinal Chemistry Stroke as a Cause of Death in Death Certificates of Patients with Dementia: A Cohort Study from the Swedish Dementia Registry
Current Alzheimer Research Update in Glaucoma Medicinal Chemistry: Emerging Evidence for the Importance of Melatonin Analogues
Current Medicinal Chemistry HCN Channels Modulators: The Need for Selectivity
Current Topics in Medicinal Chemistry Molecular Determinants of Vascular Calcification: A Bench to Bedside View
Current Molecular Medicine Exercise Rehabilitation for the Patient with Intermittent Claudication: A highly Effective yet Underutilized Treatment
Current Drug Targets - Cardiovascular & Hematological Disorders Microvascular Function/Dysfunction Downstream a Coronary Stenosis
Current Pharmaceutical Design Outcome Measures for Clinical Trials in Interstitial Lung Diseases
Current Respiratory Medicine Reviews microRNAs-based Predictor Factor in Patients with Migraine-ischemic Stroke
MicroRNA Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Insulin Resistance, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Patents on Diacylglycerol Production and Applications
Recent Patents on Chemical Engineering Cardiomyopathy of Pregnancy
Current Women`s Health Reviews Renal Endothelial Dysfunction in Diabetic Nephropathy
Cardiovascular & Hematological Disorders-Drug Targets Synthesis and Biological Potentials of Quinoline Analogues: A Review of Literature
Mini-Reviews in Organic Chemistry Prevention and Therapy of Prostate Cancer: An Update on Alternatives for Treatment and Future Perspectives
Current Drug Therapy The beneficial effect of Cape gooseberry juice on carbon tetrachloride-induced neuronal damage
CNS & Neurological Disorders - Drug Targets A Prevention of Pre-eclampsia with the Use of Acetylsalicylic Acid and Low-molecular Weight Heparin – Molecular Mechanisms
Current Pharmaceutical Biotechnology